Clovis Oncology, Inc.
Quick facts
Phase 3 pipeline
- MPDL3280A · Oncology
MPDL3280A is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 and B7-1, thereby releasing the brakes on anti-tumor immune responses.
Phase 2 pipeline
- CO-1.01 · Oncology
CO-1.01 is a poly(ADP-ribose) polymerase (PARP) inhibitor that blocks DNA repair mechanisms in cancer cells, leading to cell death.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Clovis Oncology, Inc.
What is Clovis Oncology, Inc.'s pipeline?
Clovis Oncology, Inc. has 1 drugs in Phase 3, 1 in Phase 2, 0 in Phase 1. Late-stage candidates include MPDL3280A.
Related
- Sector hub: All tracked pharma companies